Logo

Paratek's Reports Results of Nuzyra (Omadacycline) in P-III OPTIC and OASIS-1 Studies for Pneumonia and Skin Infections in Adults- Published in NEJM

Share this

Paratek's Reports Results of Nuzyra (Omadacycline) in P-III OPTIC and OASIS-1 Studies for Pneumonia and Skin Infections in Adults- Published in NEJM

Shots:

  • The P-III OPTIC and OASIS-1 studies involves assessing of Nuzyra (Omadacycline) vs moxifloxacin & linezolid in 386 & 645 patients with community acquired bacterial pneumonia (CABP) & acute bacterial skin and skin structure infections (ABSSSI) respectively
  • OPTIC study results: ECR (81.1- vs 82.7%-); IACR @PTE (87.6%- vs 85.1%); TEAEs (6.0% vs 6.7%); OASIS-1 study: ECR (84.8% vs 85.5%); IACR @PTE (86.1% vs 83.6%); mortality rate (0.3% vs 0.6%)
  • Nuzyra (qd- IV/oral) is an antibiotic- targeted for community-acquired bacterial pneumonia- acute bacterial skin and skin structure infections- also being evaluated in UTI & is approved by the US FDA for resistance diseases i.e CABP & ABSSSI

Click here Ref: Globe Newswire | Image: The Pharma Letter

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions